%0 Journal Article
%T Characterization of Major and Clinically Relevant Non-Major Bleeds in the APEX Trial
%A Adrian F. Hernandez
%A Alexander T. Cohen
%A C. Michael Gibson
%A Fahad AlKhalfan
%A Gerald Chi
%A Mathieu Kerneis
%A Megan K. Yee
%A Russell D. Hull
%A Samuel Z. Goldhaber
%A Serge Korjian
%A Tarek Nafee
%A Yazan Daaboul
%J Archive of "TH Open: Companion Journal to Thrombosis and Haemostasis".
%D 2019
%R 10.1055/s-0039-1685496
%X Background £¿Among medically ill patients treated with thromboprophylaxis, betrixaban was not associated with an increase in major bleeding compared with enoxaparin, but an increase in clinically relevant non-major (CRNM) bleeding was observed. The aim of this analysis is to describe the severity and clinical consequences of major and CRNM bleeding in the APEX trial
%K venous thromboembolism
%K betrixaban
%K acutely ill patients
%K major bleed
%K clinically relevant non-major bleeding
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6524922/